Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Astegolimab in Chronic Obstructive Pulmonary Disease
NCT05037929Phase 2Completed
- Sponsor
- Genentech
- Start
- Oct 2021
- Primary completion
- Feb 2025
- Modality
- Monoclonal Antibodies
- Countries
- 24
01
Overview
A Phase 2 trial of astegolimab in chronic obstructive pulmonary disease (COPD), sponsored by Genentech. Started Oct 2021; status: completed.
02
Drugs
astegolimab
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT05037929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05037929.